LEADER 01227nam--2200385---450-
001 990001103940203316
005 20030219140652.0
010   $a0-8247-8213-5
035   $a000110394
035   $aUSA01000110394
035   $a(ALEPH)000110394USA01
035   $a000110394
100   $a20021118d1999----km-y0enga50------ba
101 0 $aeng
102   $aUS
105   $ay|||z|||001yy
200 1 $aLow molecular weight heparin therapy$ean evaluation of clinical trials evidence$fedited by Monique Sarret, André Kher, Francis Toulemonde
210   $aNew York$aBasel$cM. Dekker$dcopyr. 1999
215   $aXI, 474 p.$d23 cm
606 0 $aEparina$xImpiego terapeutico$xCasi clinici
676   $a615.718
702  1$aSARRET,$bMonique
702  1$aKHER,$bAndré
702  1$aTOULEMONDE,$bFrancis
801  0$aIT$bSalbc$cISBD
912   $a990001103940203316
951   $a615.718 LOW$b3205 FAR$c615$d00099031
959   $aBK
969   $aFAR
979   $aMARIA$b10$c20021118$lUSA01$h1050
979   $aCHIARA$b90$c20030219$lUSA01$h1405
979   $aCHIARA$b90$c20030219$lUSA01$h1406
979   $aPATRY$b90$c20040406$lUSA01$h1716
996   $aLow molecular weight heparin therapy$9977635
997   $aUNISA